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Anaplastic large cell lymphoma (ALCL) is the second most common malignancy of T-cell phenotype. This case report describes
an unusual rapidly progressing cutaneous anaplastic large T-cell lymphoma in an HIV patient. Our patient is a twenty-year-old
African American male with perinatally acquired HIV who presented with a 2 × 2 centimeter necrotic lesion in the right 1st
toe; however, 2-3 weeks later multiple smaller lesions appeared on the anterior aspect of the right foot, ankle, and thigh. Biopsy
showed cells strongly positive for CD3 and CD30 and negative for CD56 and the ALK gene product. CT of the chest, abdomen,
and pelvis was negative for extracutaneous involvement favoring cutaneous ALCL. Patient was treated with 6 cycles of CHOP
(cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone) chemotherapy and went into complete remission. Due to
the aggressive course that this malignancy follows in HIV patients we suggest prompt treatment with systemic therapy.
1.Introduction
HIV patients are at a higher risk for opportunistic infections
and aggressive malignancies. Prior to the highly active anti-
retroviral therapy (HAART) era, malignant diseases were re-
sponsible for 10% of HIV-related deaths [1]. Since the im-
plementation of HAART therapy, it is estimated that 40%
of HIV patients are diagnosed with a neoplasm during the
course of their illness [1]. While antiretroviral therapy has
considerably decreased the incidence of Kaposi sarcoma, the
decrease in lymphoma has not been as profound. Non-
Hodgkin lymphoma (NHL) is known to be the most com-
mon malignancy that occurs in HIV-infected individuals; it
has become an AIDS deﬁning disease, and up to 23% of
this population succumbed from this illness [1]. According
to the World health Organization (WHO), Diﬀuse Large B
Cell lymphoma accounts for roughly 70% of all lymphomas
aﬀecting this population, Burkitt lymphoma approximately
20%, and indolent B cell lymphoma, plasmablastic lym-
phoma, and T cell lymphoma account for the rest; the
latest makes less than 3%. Although B-cell NHL is by far
the most encountered phenotype, HIV patients are also
aﬀected by T-cell malignancies. Linkage of AIDS and cancer
registriesintheUnited Stateshasindicated a15-foldincrease
in these lymphomas among AIDS patients when compared
with the expected incidence in the general population [2].
Anaplastic large cell lymphoma (ALCL) is the second most
common type of neoplasm of T-cell origin. It usually pre-
sents as primary systemic or cutaneous variant; although
morphologically identical, their clinical features and treat-
ments diﬀer. Many experts believe that these two entities are
diﬀerent spectrum of the same disease [2–7].
Histologically, cutaneous ALCL presents with dense lym-
phocytic inﬁltrates of the skin (Figure 1(a)). These cells clas-
sically exhibit an anaplastic, eccentric, pleomorphic-shaped2 Case Reports in Oncological Medicine
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Figure 1: (a) Skin with dense lymphoid inﬁltrate, consisting of medium to large lymphocytes with dense chromatin, irregular nuclear
contours, and occasional prominent nucleoli, shave biopsy (H&E, Original Magniﬁcation x400). (b) Patient at presentation with a single
necrotic lesion on the big toe. (c) Immunostaining negative for NPM-ALK gene product (original magniﬁcation x400). (d) Multiple satellite
lesions that appeared 3 weeks after initial presentation.
nucleuswithasingleorseverallargenucleoli,abundantcyto-
plasm, and prominent eosinophilic Golgi apparatus. How-
ever, there are other less frequent morphological variants
such as small malignant cells with clear cytoplasm and irreg-
ular nucleus, sarcomatoid, lymphohistiocytic, eosinophil-
rich, and neutrophil-rich variants. Both cutaneous and
systemic ALCLs are CD30 positive; it has been hypothesized
that this tumor marker may promote the development and
survival of malignant clones. Translocation t(2; 5) (p23;
q35) known as NPM-ALK encodes for a 80kilo-Dalton
(KDa) tyrosine kinase named Anaplastic Lymphoma Kinase
or p80. Cutaneous variant is universally negative for this
gene product while systemic ALCL is divided into ALK pos-
itive or negative [3]. The absent of this chimeric tyrosine
kinase along with its exclusive skin trophism and lack of
lymph nodes enlargement are key criteria to diﬀerentiate
cutaneous versus systemic disease. In addition, laboratory
abnormalities that include elevated lactate dehydrogenase
(LDH), anemia, and/or thrombocytopenia which are seen
in primary systemic are never encountered with cutaneous
ALCL [2, 5–7].
There is no consensus on a preferred form of treatment
for cutaneous ALCL presenting in HIV/AIDS patients; some
experts agree that single, small lesions should be treated
with radiation, while multiple lesions should be treated with
systemic chemotherapy [8]. This case report presents an un-
usually rapidly progressing cutaneous anaplastic large T-cell
lymphoma in an HIV patient.
2.CaseReport
Ourpatientisatwenty-year-oldAfricanAmericanmalewith
perinatally acquired HIV; he has been treated and followed
by infectious disease since birth. Originally, he presented
with a single 2 × 2 centimeter necrotic lesion in the right 1st
toe (Figure 1(b)). The patient claims that he ﬁrst noticed the
lesion few weeks ago, and that it has been growing rapidly
ever since. At the time of diagnosis patient’s CD4 count
was 128. Shave biopsy was taken and sent for analysis to
the National Institute of Health. The results showed cells
strongly positive for CD3 and CD30 and negative for CD
20, CD56, and for p80 tyrosine kinase (Figure 1(c)). CTCase Reports in Oncological Medicine 3
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Figure 2: Resolution of all lesions after 6cycles of CHOP chemotherapy.
of the chest, abdomen, and pelvis was negative for extra-
cutaneous involvement. Based on the clinical presentation,
immunostaining results, and imaging study, the patient was
diagnosed with primary cutaneous ALCL. Additional lesions
appearedonthelateralaspectofthefoot(Figure 1(d)),ankle,
and thigh 3 weeks after patient ﬁrst came to our clinic. After
careful evaluation of the literature, we decided to treat the
patient with six cycles of CHOP (cyclophosphamide, hy-
droxydaunorubicin, vincristine, and prednisone).
3. Results
Therapy course was complicated by an episode of neutrope-
nia that resolved after a treatment holiday of one week. Each
subsequent cycle of chemotherapy was followed by a single
injection of pegﬁlgrastim to prevent treatment delays related
to neutropenia. Upon treatment completion, total resolution
of the primary lesion located in the ﬁrst toe as well as
secondary lesions as described above was observed (Figures
2(a) and 2(b)).
4. Discussion
Non-Hodgkin lymphoma (NHL) has become one of the
most common AIDS deﬁning illnesses; although T-cell lym-
phomas remain rare among HIV patient, they occur more
frequently than in immunocompetent individuals [2]. Pri-
mary cutaneous ALCL is a rare illness frequently seen in
older adults and rarely in pediatric population [5]. It has
a tendency to inﬁltrate the dermis and subcutaneous tissue
and typically presents as a solitary, localized skin lesion with
or without necrosis or ulceration. However, according to
WHO a small percentage of cutaneous ALCL presents with
multifocal disease. Malignant inﬁltration of organs other
than the skin is extremely rare; it is occasionally seen in
advance untreated cases. Interestingly, this tumor can show
spontaneous regression, a behavior commonly seen with sin-
glesmalllesions;unfortunately,italsohasatendencytorecur
even after complete spontaneous remission [2, 5].
Neither at the time of diagnosis nor during follow-up did
our patient complained of any systemic symptoms, which
correlateswiththetypicalindolentpresentationofcutaneous
ALCL. This seemingly benign onset was contrasted by rapid
appearance of multiple smaller satellite lesions with no ev-
idence of systemic disease. It has been hypothesized that
defect in cell-mediated immunity and activation secondary
to HIV infection is one of the factors responsible for these
patient’s increased risk for rare, aggressive malignancies. In
addition, this viral infection is associated with a cytokine
proﬁle change that favors Th2 cytokines production over
its Th1 counterpart. The enhanced production of these
cytokines increases HIV virus proliferation, virus immune
evasion, transcription of some oncogenes, and accumulation
of genetic errors favoring the development of premalignant
and malignant conditions [9].
In immunocompetent patients, cutaneous variant ALCL
commonly presents as solitary, indolent slowly progressing
lesion. Radiation therapy is the preferred treatment of soli-
tary or localized cutaneous CD30+ (Ki-1) anaplastic large-
cell lymphoma (cutaneous CD30+ ALCL). Doses ranging
from 3000 to 3600cGy are associated with response rates
above 90% [9, 10]. Systemic chemotherapy with multiple
or single agents is reserved for patients that do not respond
to local therapy, for those who have disease presenting as
multiple lesions, and for those with extra cutaneous tumor
spread [11]. Methotrexate is the most commonly used
agentin thesesettings. Treatmentselection forimmunocom-
promised patient can be very challenging. There is very
limited literature regarding treatments and their overall
eﬀectiveness in HIV patients presenting with multifocal,
rapidly progressing disease. However, based on previously
published articles by Arzoo et al., systemic chemotherapy
alone has been shown to induce complete remission in a few
cases of HIV patients aﬀected by this cancer. Based on our
patient’s clinical presentation and the available research, we
decided to treat him with CHOP [6, 11–13].
Unfortunately, this tumor has a tendency to recur, even
after long disease-free intervals. According to the literature
review CHOP therapy does not prevent future relapses
[6, 11]. Newer classes of drugs such as histone deacetylase
(HDAC) inhibitors are now available as treatment alter-
natives. Recently Romidepsin was approved for treatment
of cutaneous ALCL for patients that had received systemic4 Case Reports in Oncological Medicine
chemotherapy at least once [11]. However, the role of this
medication is not clear in immunocompromised patients.
Immunomodulatory drugs like lenalidomide and thalido-
mide have been evaluated from the treatment of this malig-
nancy. They inhibit cell growth by inducing cell cycle arrest,
reduce the production of proangiogenic cytokines such as
vascular endothelial grow factor (VEGF), and stimulate
T cells to enhance their antitumor activity. SGN-30 is a
chimericanti-CD30monoclonalantibodypresentlyinphase
II clinical trials. This novel agent has shown considerable
activity against cutaneous ALCL. Bortezomib, a proteasome
inhibitor, is active against this malignancy as well. Preclinical
data on the use of Bortezomib as single agent chemotherapy
for relapsing/refractory T-cell lymphoma have been associ-
ated with an overall response rate of 67% [11]. Clinical trials
to evaluate the eﬀectiveness of proteasome inhibitors and
HDAC combo treatment in relapsing/refractory T-cell NHL,
including cutaneous ALCL, are ongoing [6, 11–13]. In some
casesautologousandallogeneicbonemarrowtransplantmay
be required, but the data are limited [10].
ThisarticledescribesacaseofaggressivecutaneousALCL
in an HIV patient, its management, and clinical outcome.
To the best of our knowledge, there are no reported cases
of patients with perinatally acquired HIV aﬀected with this
illness. The malignant course followed by this neoplasm is
also unorthodox. Thus, based on the disease’s presentation
in our patient and complete remission observed following
treatment, we conclude that HIV patients aﬀected by cuta-
neous ALCL are readily treated with CHOP chemotherapy
due to the aggressive course that this tumor tends to follow
in this group of patients.
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